	US 12,281,155 B1
	Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof
Antoine Pau, Paris (FR); Hugo Mouquet, Paris (FR); and Cyril Planchais, Paris (FR)
Assigned to INSTITUT PASTEUR, Paris (FR); and SPIKIMM, Paris (FR)
Filed by INSTITUT PASTEUR, Paris (FR); and SPIKIMM, Paris (FR)
Filed on Jan. 19, 2024, as Appl. No. 18/417,613.
Int. Cl. C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); C12N 15/63 (2006.01); G01N 33/569 (2006.01)

CPC C07K 16/1003 (2023.08) [A61P 31/14 (2018.01); C12N 15/63 (2013.01); G01N 33/56983 (2013.01); A61K 2039/507 (2013.01); C07K 2317/14 (2013.01); C07K 2317/41 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01)]

21 Claims

1. An antibody of any isotype or species that binds to the viral Spike protein receptor binding-domain (RBD) of Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), or antigen-binding fragment thereof, comprising:

(i) a heavy chain variable domain, or fragment thereof, comprising:

a HCDR1 of SEQ ID NO. 1,

a HCDR2 selected from SEQ ID NO. 2 and SEQ ID NO. 20, and

a HCDR3 of SEQ ID NO. 3, and

(ii) a light chain variable domain, or fragment thereof, comprising:

a LCDR1 selected from SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 24 and SEQ ID NO. 25,

a LCDR2 of SEQ ID NO. 10, and

a LCDR3 selected from SEQ ID NO. 11 and SEQ ID NO. 27, and

(iii) a HFR3 of the amino acid sequence RFTISXDNSKNTLYLQMNSLRAEDTAVYYCAR (SEQ ID NO. 28) wherein X means an amino acid selected from Alanine, Tyrosine and Threonine.